BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bigley AB, Baker FL, Simpson RJ. Cytomegalovirus: an unlikely ally in the fight against blood cancers? Clin Exp Immunol 2018;193:265-74. [PMID: 29737525 DOI: 10.1111/cei.13152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Palamarchuk AI, Alekseeva NA, Streltsova MA, Ustiuzhanina MO, Kobyzeva PA, Kust SA, Grechikhina MV, Boyko AA, Shustova OA, Sapozhnikov AM, Kovalenko EI. Increased Susceptibility of the CD57- NK Cells Expressing KIR2DL2/3 and NKG2C to iCasp9 Gene Retroviral Transduction and the Relationships with Proliferative Potential, Activation Degree, and Death Induction Response. Int J Mol Sci 2021;22:13326. [PMID: 34948123 DOI: 10.3390/ijms222413326] [Reference Citation Analysis]
2 Han SH, Yoo SG, Do Han K, La Y, Kwon DE, Lee KH. The Incidence and Effect of Cytomegalovirus Disease on Mortality in Transplant Recipients and General Population: Real-world Nationwide Cohort Data. Int J Med Sci 2021;18:3333-41. [PMID: 34400903 DOI: 10.7150/ijms.62621] [Reference Citation Analysis]
3 Gaballa A, Alagrafi F, Uhlin M, Stikvoort A. Revisiting the Role of γδ T Cells in Anti-CMV Immune Response after Transplantation. Viruses 2021;13:1031. [PMID: 34072610 DOI: 10.3390/v13061031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Horowitz NB, Mohammad I, Moreno-Nieves UY, Koliesnik I, Tran Q, Sunwoo JB. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. Front Immunol 2021;12:648580. [PMID: 33968039 DOI: 10.3389/fimmu.2021.648580] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Mardani M, Abolghasemi S, Shabani S, Tavakoli F, Saeedi A, Parkhideh S, Hajifathali A. The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Iran J Microbiol 2020;12:636-43. [PMID: 33613920 DOI: 10.18502/ijm.v12i6.5040] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Jaiswal SR, Bhakuni P, Aiyer HM, Soni M, Bansal S, Chakrabarti S. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies. Biol Blood Marrow Transplant 2020;26:1469-76. [PMID: 32428732 DOI: 10.1016/j.bbmt.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Herbein G, Nehme Z. Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy? Mol Ther Oncolytics 2020;17:1-8. [PMID: 32300639 DOI: 10.1016/j.omto.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Massara L, Khairallah C, Yared N, Pitard V, Rousseau B, Izotte J, Giese A, Dubus P, Gauthereau X, Déchanet-Merville J, Capone M. Uncovering the Anticancer Potential of Murine Cytomegalovirus against Human Colon Cancer Cells. Mol Ther Oncolytics 2020;16:250-61. [PMID: 32140563 DOI: 10.1016/j.omto.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jaiswal SR, Chakrabarti S. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation. Immunotherapy 2019;11:1221-30. [DOI: 10.2217/imt-2019-0037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]